Sirtex & Magle PharmaCept Partner to Shape the Future of Embolization

15/01/2026

Magle Group is pleased to announce that Magle PharmaCept, together with Sirtex, will attend GEST MSK, a congress focused on Musculoskeletal (MSK) Embolization, taking place January 17–18, 2026, in Paris, France.

The meeting brings together leading experts in interventional radiology to discuss advances in minimally invasive treatments for musculoskeletal conditions.

Musculoskeletal pain is a leading cause of disability, particularly among aging patients. For many individuals, traditional pharmacological treatments do not provide sufficient relief or are not suitable due to comorbidities. MSK embolization is gaining increasing attention as a safe, minimally invasive treatment option that addresses this significant unmet medical need.

GEST MSK is recognized as an important forum for interventional radiologists, offering in-depth discussions on patient evaluation, diagnosis, and treatment strategies. The program includes interactive sessions, expert panels, and masterclasses aimed at advancing clinical practice and knowledge in MSK embolization.

The joint participation of Magle PharmaCept and Sirtex at GEST MSK reflects a shared commitment to innovation, collaboration, and the advancement of embolization therapies — partnering to help shape the future of embolization.

Magle Group’s participation at GEST MSK reflects its ongoing commitment to advancing science, supporting clinicians, and improving patients’ quality of life through innovative and degradable embolic technologies.